002630 — Orient Bio Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Market Cap
KR₩161bn
Enterprise Value
KR₩137bn
Revenue
KR₩28bn

Annual income statement for Orient Bio, fiscal year end - March 31st, KRW millions except per share, conversion factor applied.

	2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	37,699	25,180	26,276	28,819	28,005
Cost of Revenue
Gross Profit	7,200	6,196	9,014	9,824	9,584
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	49,998	35,404	31,668	27,566	28,651
Operating Profit	-12,299	-10,224	-5,392	1,253	-646
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-11,644	-22,490	-3,361	-12,591	12,871
Provision for Income Taxes
Net Income After Taxes	-11,644	-22,455	-3,430	-12,424	12,871
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-10,881	-15,634	34,198	-12,424	12,871
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-10,881	-15,634	34,198	-12,424	12,871
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-96.6	-169	-20.1	-104	108
Dividends per Share